These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11472206)

  • 81. Targeting a Subpocket in Trypanosoma brucei Phosphodiesterase B1 (TbrPDEB1) Enables the Structure-Based Discovery of Selective Inhibitors with Trypanocidal Activity.
    Blaazer AR; Singh AK; de Heuvel E; Edink E; Orrling KM; Veerman JJN; van den Bergh T; Jansen C; Balasubramaniam E; Mooij WJ; Custers H; Sijm M; Tagoe DNA; Kalejaiye TD; Munday JC; Tenor H; Matheeussen A; Wijtmans M; Siderius M; de Graaf C; Maes L; de Koning HP; Bailey DS; Sterk GJ; de Esch IJP; Brown DG; Leurs R
    J Med Chem; 2018 May; 61(9):3870-3888. PubMed ID: 29672041
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.
    Duffy S; Sykes ML; Jones AJ; Shelper TB; Simpson M; Lang R; Poulsen SA; Sleebs BE; Avery VM
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674055
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!
    Tagoe DN; Kalejaiye TD; de Koning HP
    Front Pharmacol; 2015; 6():185. PubMed ID: 26441645
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).
    Woodring JL; Bland ND; Ochiana SO; Campbell RK; Pollastri MP
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5971-4. PubMed ID: 24042005
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets.
    de Koning HP; Gould MK; Sterk GJ; Tenor H; Kunz S; Luginbuehl E; Seebeck T
    J Infect Dis; 2012 Jul; 206(2):229-37. PubMed ID: 22291195
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
    Hoffmann M; Kumar G; Schafer P; Cedzik D; Capone L; Fong KL; Gu Z; Heller D; Feng H; Surapaneni S; Laskin O; Wu A
    Xenobiotica; 2011 Dec; 41(12):1063-75. PubMed ID: 21859393
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
    Cashman JR; Voelker T; Zhang HT; O'Donnell JM
    J Med Chem; 2009 Mar; 52(6):1530-9. PubMed ID: 19256502
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.
    Gale DD; Hofer P; Spina D; Seeds EA; Banner KH; Harrison S; Douglas G; Matsumoto T; Page CP; Wong RH; Jordan S; Smith F; Banik N; Halushka PV; Cavalla D; Rotshteyn Y; Kyle DJ; Burch RM; Chasin M
    Pulm Pharmacol Ther; 2003; 16(2):97-104. PubMed ID: 12670778
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Couwenberg D; Hatzelmann A; Sterk GJ; Goubitz K; Schenk H; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2526-33. PubMed ID: 12036361
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.
    Van der Mey M; Hatzelmann A; Van der Laan IJ; Sterk GJ; Thibaut U; Timmerman H
    J Med Chem; 2001 Aug; 44(16):2511-22. PubMed ID: 11472205
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Hatzelmann A; Van der Laan IJ; Sterk GJ; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2520-5. PubMed ID: 12036360
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
    Van der Mey M; Bommelé KM; Boss H; Hatzelmann A; Van Slingerland M; Sterk GJ; Timmerman H
    J Med Chem; 2003 May; 46(10):2008-16. PubMed ID: 12723963
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2001 Jan; 11(1):33-7. PubMed ID: 11140727
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Hatzelmann A; Van Klink GP; Van der Laan IJ; Sterk GJ; Thibaut U; Ulrich WR; Timmerman H
    J Med Chem; 2001 Aug; 44(16):2523-35. PubMed ID: 11472206
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.